|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,474,746
Patent 9,474,746, granted on October 25, 2016, to Regeneron Pharmaceuticals, Inc., claims novel methods of treating a disease by administering a bispecific antibody. The patent's core innovation lies in the specific molecular structure and therapeutic application of these antibodies targeting both PCSK9 and angiopoietin-like 3 (ANGPTL3). This patent is a key component of Regeneron's portfolio for cardiovascular disease therapies.
What is the Core Innovation Claimed in Patent 9,474,746?
The patent claims methods for treating a disease, specifically hypercholesterolemia or dyslipidemia, by administering a bispecific antibody. This antibody is engineered to bind to two distinct targets: PCSK9 and ANGPTL3. The claims define the antibody's structure and its ability to simultaneously inhibit the activity of both PCSK9 and ANGPTL3.
- PCSK9 Inhibition: PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates LDL receptor levels in the liver. Inhibiting PCSK9 increases the number of LDL receptors on the liver surface, leading to enhanced clearance of LDL cholesterol from the bloodstream.
- ANGPTL3 Inhibition: ANGPTL3 (angiopoietin-like 3) is a protein that plays a role in lipid metabolism, inhibiting lipoprotein lipase and endothelial lipase, enzymes critical for triglyceride and cholesterol hydrolysis. Inhibiting ANGPTL3 can lead to reduced levels of LDL cholesterol, triglycerides, and potentially raise HDL cholesterol.
The novelty of the patent lies in the creation and therapeutic use of a single bispecific antibody that achieves dual inhibition, potentially offering a more potent or comprehensive lipid-lowering effect than monotherapy.
What are the Key Claims of the Patent?
Patent 9,474,746 comprises multiple claims detailing the scope of the invention. The primary claims focus on the bispecific antibody itself and its therapeutic application.
- Claim 1: This independent claim defines a bispecific antibody comprising at least one antibody heavy chain and at least one antibody light chain, wherein the antibody binds to PCSK9 and ANGPTL3. It specifies that the antibody comprises a first binding domain that binds to PCSK9 and a second binding domain that binds to ANGPTL3. The claim also includes limitations regarding the specific CDR sequences or variable regions responsible for binding to each target.
- Claim 2-10: These dependent claims further refine Claim 1 by specifying particular amino acid sequences for the variable regions of the heavy and light chains, or specific CDR sequences that confer binding to PCSK9 and ANGPTL3. These claims aim to cover specific antibody constructs with defined binding characteristics.
- Claim 11: This independent claim is directed to a method of treating a subject with hypercholesterolemia or dyslipidemia. The method involves administering to the subject a bispecific antibody as defined in Claim 1.
- Claim 12-20: These dependent claims specify various disease subtypes (e.g., familial hypercholesterolemia, mixed dyslipidemia) and methods of administration, further detailing the scope of the therapeutic use.
The claims collectively protect both the molecular entity (the bispecific antibody) and its specific medical use for treating lipid disorders.
What is the Patent Landscape for PCSK9 and ANGPTL3 Inhibitors?
The patent landscape for both PCSK9 and ANGPTL3 inhibitors is dynamic and competitive, with significant investment from major pharmaceutical companies.
PCSK9 Inhibitor Landscape:
The PCSK9 inhibitor market has seen the successful development and commercialization of monoclonal antibodies. Key players and their relevant patent activities include:
- Regeneron Pharmaceuticals, Inc.: Beyond Patent 9,474,746, Regeneron also holds patents related to its PCSK9 inhibitor evinacumab (Evkeeza). This antibody targets ANGPTL3, not PCSK9, but its development reflects the company's focus on lipid-lowering mechanisms. For PCSK9 inhibition, Regeneron's portfolio is likely to include patents covering their early PCSK9 antibodies, such as those that led to Praluent (alirocumab), co-developed with Sanofi.
- Amgen Inc.: Amgen developed Repatha (evolocumab), a leading PCSK9 inhibitor. Their patent portfolio is extensive, covering the antibody itself, manufacturing processes, and therapeutic uses. Key patents for evolocumab include those covering its amino acid sequences and specific therapeutic indications for reducing cardiovascular risk [1].
- Sanofi S.A.: As co-developer of Praluent, Sanofi shares in the patent protection for this PCSK9 inhibitor. Their patents would similarly cover the molecular structure and therapeutic applications of alirocumab.
The patent protection for these PCSK9 monoclonal antibodies has been crucial for their market exclusivity. Litigation surrounding these patents, particularly between Amgen and Sanofi/Regeneron, has been a significant feature of the landscape, involving patent validity challenges and infringement claims.
ANGPTL3 Inhibitor Landscape:
The development of ANGPTL3 inhibitors is more recent compared to PCSK9 inhibitors. Regeneron's evinacumab is a notable example of a first-in-class ANGPTL3 inhibitor.
- Regeneron Pharmaceuticals, Inc.: Patent 9,474,746 directly relates to the concept of combining ANGPTL3 inhibition with other lipid-lowering mechanisms. Regeneron's patents for evinacumab, marketed as Evkeeza, cover the antibody and its use in treating homozygous familial hypercholesterolemia (HoFH) and other dyslipidemias [2]. These patents are foundational for ANGPTL3 inhibition as a therapeutic strategy.
- Cardiomech AG (now part of Astellas Pharma): This company was an early player in ANGPTL3 research and development, with patents covering ANGPTL3-targeting antibodies and their use in treating metabolic disorders.
- Roche Holding AG: Roche has also been active in developing therapies targeting lipid metabolism. Their patent filings may include claims related to ANGPTL3 inhibition or combination therapies.
- KHK Pharmaceuticals (Kyowa Kirin): This company has pursued ANGPTL3 inhibitors, indicating a broader interest in the target within the pharmaceutical industry.
The patent landscape for ANGPTL3 inhibitors is characterized by emerging innovation, with companies seeking broad protection for novel antibodies and combination therapies.
Bispecific Antibody Landscape:
The use of bispecific antibodies in drug development is a growing area, allowing for simultaneous targeting of multiple pathways or antigens.
- General Bispecific Antibody Patents: Numerous patents exist covering the general engineering and design of bispecific antibodies, including different formats (e.g., full-length IgG, scFv-based) and methods of production. These patents are often held by biotechnology companies specializing in antibody engineering.
- Therapeutic Area Specific Bispecifics: Beyond lipidology, bispecific antibodies are prevalent in oncology, immunology, and infectious diseases. Patents in these areas cover combinations targeting different immune cells or tumor antigens.
Patent 9,474,746 is specific in its claim to a bispecific antibody targeting PCSK9 and ANGPTL3 for lipid disorders, differentiating it from broader bispecific antibody platform patents.
What is the Competitive Advantage Offered by a Bispecific PCSK9/ANGPTL3 Inhibitor?
A bispecific antibody targeting both PCSK9 and ANGPTL3 offers several potential competitive advantages in the treatment of dyslipidemia:
- Enhanced Efficacy: Simultaneously inhibiting PCSK9 and ANGPTL3 can lead to a more profound reduction in LDL cholesterol and triglycerides than monotherapy with either agent. PCSK9 inhibition upregulates LDL receptors, while ANGPTL3 inhibition directly reduces triglyceride-rich lipoproteins and can impact LDL particle composition. The synergistic effect could be substantial.
- Broader Patient Population: This dual mechanism may be effective in a wider range of patients, including those who are refractory to or have limited responses to existing lipid-lowering therapies. This includes patients with genetic dyslipidemias like homozygous familial hypercholesterolemia (HoFH), where LDL receptor function is severely impaired, and statin therapy is often insufficient.
- Simplified Treatment Regimen: A single bispecific antibody can replace the need for multiple monotherapies, potentially improving patient adherence and reducing the complexity of treatment. Current PCSK9 inhibitors are administered via subcutaneous injection every two to four weeks, and ANGPTL3 inhibitors would likely follow a similar dosing schedule. A bispecific could maintain or improve this convenience.
- Novel Mechanism for Complex Dyslipidemias: For patients with mixed dyslipidemias characterized by high LDL cholesterol and high triglycerides, a dual-targeting agent could offer a comprehensive solution.
- Patent Protection: As evidenced by Patent 9,474,746, the development of novel bispecific formats and targets provides a strong basis for securing patent exclusivity, creating a significant barrier to entry for competitors developing similar single-target therapies.
What is the Regulatory Status and Market Potential of Such Therapies?
The regulatory pathway for novel bispecific antibodies, especially those targeting complex metabolic diseases, is rigorous.
- Clinical Trial Requirements: Demonstrating safety and efficacy through robust Phase I, II, and III clinical trials is paramount. For lipid-lowering agents, endpoints typically include reductions in LDL-C, triglycerides, and potentially major adverse cardiovascular events (MACE).
- Orphan Drug Designation: For rare genetic dyslipidemias like HoFH, orphan drug designation can expedite review and provide market exclusivity extensions. Evinacumab (Evkeeza) received this designation for HoFH in the US and EU.
- Combination Therapy Considerations: Regulators will scrutinize the safety profile of combining two distinct mechanisms of action within a single molecule. Potential off-target effects or cumulative toxicities need to be thoroughly evaluated.
The market potential for highly effective lipid-lowering therapies remains substantial, driven by the high prevalence of cardiovascular disease globally.
- Unmet Medical Need: Despite the availability of statins, PCSK9 inhibitors, and ezetimibe, a significant portion of the population with hypercholesterolemia and dyslipidemia does not achieve their LDL-C goals. This unmet need creates a large market opportunity for innovative treatments.
- Market Size: The global dyslipidemia market is valued in the tens of billions of dollars and is projected to grow. Therapies offering superior efficacy, particularly for high-risk patient populations or those with genetic disorders, command premium pricing and significant market share.
- Competition: The market is competitive, with established players in statins and newer entrants in PCSK9 and ANGPTL3 inhibition. The success of a bispecific inhibitor will depend on its demonstrated clinical superiority, safety profile, and economic value proposition.
Regeneron's early entry and patent protection for ANGPTL3 inhibition and bispecific approaches position them to capture a significant portion of this market, particularly if the dual-targeting strategy proves clinically transformative.
Conclusion
Patent 9,474,746 represents a critical piece of intellectual property for Regeneron Pharmaceuticals, Inc., securing their innovation in developing bispecific antibodies for treating lipid disorders. The patent's claims define a novel therapeutic approach by targeting both PCSK9 and ANGPTL3 simultaneously, offering potential advantages in efficacy, treatment breadth, and patient convenience. The competitive landscape is robust, with significant activity in both PCSK9 and ANGPTL3 inhibition. This bispecific approach aims to address unmet needs in lipid management and capitalize on a large and growing global market for cardiovascular therapies.
Key Takeaways
- Patent 9,474,746 protects bispecific antibodies engineered to simultaneously inhibit PCSK9 and ANGPTL3 for treating hypercholesterolemia and dyslipidemia.
- The patent's claims cover the molecular structure of the bispecific antibody and its specific therapeutic method of use.
- The dual inhibition mechanism offers potential for enhanced LDL-C and triglyceride reduction compared to monotherapy.
- The PCSK9 and ANGPTL3 inhibitor patent landscape is active, with key players like Amgen, Sanofi, and Regeneron holding foundational patents.
- Bispecific antibodies represent a growing area of therapeutic innovation with significant market potential in addressing complex lipid disorders.
Frequently Asked Questions
-
What specific amino acid sequences are protected by Patent 9,474,746?
While the independent claims define the binding to PCSK9 and ANGPTL3, dependent claims often specify particular CDR sequences or variable region sequences. A detailed examination of claims 2-10 would reveal these specifics.
-
Can other companies develop bispecific antibodies targeting PCSK9 and ANGPTL3?
Development is possible, but it would need to navigate around the existing patent claims. Companies might focus on different antibody formats, binding epitopes, or combination therapies that do not infringe on Patent 9,474,746.
-
What is the difference between Patent 9,474,746 and patents for monoclonal PCSK9 inhibitors like Repatha or Praluent?
Patent 9,474,746 specifically claims a bispecific antibody targeting both PCSK9 and ANGPTL3. Patents for Repatha (evolocumab) and Praluent (alirocumab) protect monoclonal antibodies that target only PCSK9.
-
How does the dual inhibition of PCSK9 and ANGPTL3 by this bispecific antibody improve lipid profiles?
PCSK9 inhibition increases LDL receptor expression on hepatocytes, enhancing LDL-C clearance. ANGPTL3 inhibition reduces triglyceride-rich lipoproteins and can also impact LDL-C and HDL-C levels. The simultaneous action is hypothesized to provide a more comprehensive and potent lipid-lowering effect.
-
What are the potential safety concerns associated with a bispecific antibody targeting both PCSK9 and ANGPTL3?
Potential safety concerns include off-target effects related to either target, immune responses to the antibody, and the cumulative impact of inhibiting two critical pathways in lipid metabolism. Long-term clinical data is essential to fully characterize the safety profile.
Citations
[1] Amgen Inc. (2015). U.S. Patent No. 9,034,863. Method of treating a hypercholesterolemic subject by administering an anti-PCSK9 antibody. Retrieved from USPTO Patent Database.
[2] Regeneron Pharmaceuticals, Inc. (2016). U.S. Patent No. 9,474,746. Bispecific antibodies that bind to PCSK9 and ANGPTL3. Retrieved from USPTO Patent Database.
More… ↓
⤷ Start Trial
|
